{"id":7252,"date":"2013-07-23T19:04:30","date_gmt":"2013-07-24T00:04:30","guid":{"rendered":"http:\/\/medicinainterna.com.mx\/?p=7252"},"modified":"2013-07-23T19:04:30","modified_gmt":"2013-07-24T00:04:30","slug":"criterio-international-prognostic-system-hasenclever-score-para-grupos-de-riesgo-con-enfermedad-avanzada","status":"publish","type":"post","link":"https:\/\/medicinainterna.com.mx\/?p=7252","title":{"rendered":"Criterio International Prognostic System (Hasenclever Score) para grupos de riesgo con enfermedad avanzada."},"content":{"rendered":"<h3><\/h3>\n<table width=\"287\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"top\" width=\"147\"><i>Variables con impacto pron\u00f3stico adverso<\/i><\/td>\n<td valign=\"top\" width=\"140\"><i>Supervivencia libre de progresi\u00f3n, a los 5 a\u00f1os, de acuerdo con el n\u00famero de factores de riesgo<\/i><\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"147\">Edad mayor de 50 a\u00f1os,<\/p>\n<p>Sexo masculino,<\/p>\n<p>Estadio IV,<\/p>\n<p>Hb menor de 10 g\/dL,<\/p>\n<p>Alb\u00famina menor de 4 g\/dL,<\/p>\n<p>Leucocitos mayor o igual a 15x10E9\/L,<\/p>\n<p>Linfocitos menor de 0.6x10E9\/L (o menor del 8% en el recuento diferencial).<\/td>\n<td valign=\"top\" width=\"140\">\n<p align=\"center\">0 factor: 84%<\/p>\n<p align=\"center\">1 factor: 77%<\/p>\n<p align=\"center\">2 factor: 67%<\/p>\n<p align=\"center\">3 factor: 60%<\/p>\n<p align=\"center\">4 factor: 51%<\/p>\n<p align=\"center\">5 factor: 42%<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Fuente: Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2032s disease. International Prognostic Factors Project on Advanced Hodgkin\u2032s Disease. N Engl J Med. 1998;339(21):1506-14.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Variables con impacto pron\u00f3stico adverso Supervivencia libre de progresi\u00f3n, a los 5 a\u00f1os, de acuerdo con el n\u00famero de factores de riesgo Edad mayor de 50 a\u00f1os, Sexo masculino, Estadio IV, Hb menor de 10 g\/dL, Alb\u00famina menor de 4 g\/dL, Leucocitos mayor o igual a 15x10E9\/L, Linfocitos menor de 0.6x10E9\/L (o menor del 8% &hellip; <a href=\"https:\/\/medicinainterna.com.mx\/?p=7252\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Criterio International Prognostic System (Hasenclever Score) para grupos de riesgo con enfermedad avanzada.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-7252","post","type-post","status-publish","format-standard","hentry","category-hematologia"],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/posts\/7252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7252"}],"version-history":[{"count":0,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/posts\/7252\/revisions"}],"wp:attachment":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}